The FDA has approved the first treatment for severe hypoglycemia that can be administered without an injection, the agency announced on July 24.
New warnings will be placed on saxagliptin and alogliptin about the potential risk of heart failure, particularly in patients with heart or kidney disease, the FDA announced on April 5. ... The FDA recommends that clinicians consider discontinuing
A new glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide (Trulicity), was approved to treat type 2 diabetes, along with diet and exercise, the FDA recently announced. ... The FDA is requiring several postmarketing studies, including trials in
https://diabetes.acponline.org/archives/2017/09/08/8.htm. The FDA approved a new indication for liraglutide to reduce the risk of myocardial infarction, stroke, and cardiovascular death in adults ... The FDA recently approved a new indication for
The FDA provided recommendations to patients, caregivers, and clinicians on the proper use of both standard and safety pen needles to inject medicines in a Sept.
https://diabetes.acponline.org/archives/2019/10/11/9.htm. The FDA has approved an oral formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to help improve ... The FDA recently approved semaglutide (Rybelsus) oral tablets, the
FDA to improve blood glucose control in adults with type 2 diabetes, along with diet and exercise. ... Alogliptin (Nesina) and two new combination drugs (alogliptin and metformin hydrochloride [Kazano] and alogliptin and pioglitazone [Oseni]) were
Certain batches of NovoPen Echo insulin cartridge holders are being recalled by the manufacturer because they may crack or break if exposed to certain chemicals, such as cleaning agents, the FDA ... The FDA also announced on May 19 that it approved the
The FDA has approved a new indication for empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults, the agency announced on Feb. ... The drug must not be used in patients who have had a previous
The FDA is requiring postmarketing studies related to pediatric use, risks of MTC, and cardiovascular outcomes. ... The most common side effects are diarrhea, nausea, and injection site reactions, according to an FDA press release.